Insight Molecular Diagnostics
IMDX
75 hedge funds and large institutions have $59.4M invested in Insight Molecular Diagnostics in 2022 Q2 according to their latest regulatory filings, with 14 funds opening new positions, 15 increasing their positions, 26 reducing their positions, and 23 closing their positions.
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
0.05% less ownership
Funds ownership: 2.95% → 2.9% (-0.05%)
13% less funds holding
Funds holding: 86 → 75 (-11)
27% less capital invested
Capital invested by funds: $81.2M → $59.4M (-$21.8M)
39% less first-time investments, than exits
New positions opened: 14 | Existing positions closed: 23
42% less repeat investments, than reductions
Existing positions increased: 15 | Existing positions reduced: 26
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AIC
AWM Investment Company
New York
|
+$8.53M |
| 2 |
BC
Broadwood Capital
New York
|
+$6.83M |
| 3 |
PVI
Pura Vida Investments
New York
|
+$6.63M |
| 4 |
Millennium Management
New York
|
+$1.13M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$410K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
-$2.95M |
| 2 |
N
Nuveen
Charlotte,
North Carolina
|
-$1.45M |
| 3 |
State Street
Boston,
Massachusetts
|
-$1.17M |
| 4 |
O
OrbiMed
New York
|
-$746K |
| 5 |
Northern Trust
Chicago,
Illinois
|
-$390K |
IMDX Hedge Fund Activity: Q2 2022 in Review
75 of the 5,936 institutional investors tracked by Wall St. Rank reported a position in Insight Molecular Diagnostics (IMDX) for Q2 2022, worth a combined $59.4M — down 27% from $81.2M a quarter earlier.
Sellers outnumbered buyers: 23 funds closed out of IMDX and 14 opened new positions — a net loss of 9 holders — while 26 trimmed existing stakes and 15 added.
The largest buyer was AWM Investment Company, adding an estimated $8.53M. The largest seller was BlackRock, cutting an estimated $2.95M.
- 75 institutional investors held Insight Molecular Diagnostics (IMDX) as of Q2 2022, down from 86 in Q1 2022.
- Funds reported $59.4M of Insight Molecular Diagnostics stock for Q2 2022, down 27% quarter-over-quarter.
- 14 funds opened new Insight Molecular Diagnostics positions in Q2 2022 and 23 closed out, a net change of -9 holders.
- The largest Insight Molecular Diagnostics buyer in Q2 2022 was AWM Investment Company, an estimated $8.53M added.
- The largest Insight Molecular Diagnostics seller in Q2 2022 was BlackRock, an estimated $2.95M sold.
Based on aggregated 13F filings for Q2 2022.